Assessment of bone lesions with 18 F-FDG PET/MRI in patients with nasopharyngeal carcinoma.

Journal and index pages often block iframe embedding. This reader keeps the evidence details in Orthonotes and leaves the source page one click away.

Abstract

[Indexed for MEDLINE] 14. Eur J Nucl Med Mol Imaging. 2025 Jul;52(9):3087-3100. doi: 10.1007/s00259-025-07171-9. Epub 2025 Mar 8. Clinical comprehensive evaluation of [(18)F]AlF-FAP-NUR PET: multi-time-point imaging, head-to-head comparison with [(18)F]FDG. Zhang Z(#)(1), Liu S(#)(1), Liang S(#)(1), Bai X(1), He Y(1), Zhong J(1), Liang W(1), Hou P(1), Zhong H(1), Wu T(2), Ng YL(2), Zhang J(1), Ke M(1), Fu Y(1), Wang X(3). Author information: (1)Department of Nuclear Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510120, China. (2)United Imaging Research Institute, United Imaging Healthcare Group Co., Ltd, Shanghai, 201807, China. (3)Department of Nuclear Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510120, China. 71lu@163.com. (#)Contributed equally PURPOSE: This study was designed to investigate the clinical feasibility of [18F]AlF-FAP-NUR, including the pharmacokinetics, radiation dosimetry estimation, and the head-to-head comparison with [18F]FDG. The head-to-head comparison study was designed to investigate the radiotracer uptake of [18F]AlF-FAP-NUR, to detect the primary and metastatic lesions in patients with various solid cancers, and to compare the results with those of [18F]FDG PET/CT. The correlation of FAP-expression (H-scores) and standardized uptake values (SUVs) derived from [18F]AlF-FAP-NUR were also included. METHODS: Ten patients participated in a multi-time-point imaging protocol aimed at assessing pharmacokinetics and estimating radiation dosimetry. Radiation dosimetry calculations were performed using the OLINDA/EXM 2.0 software. For the comparative analysis between [18F]AlF-FAP-NUR and [18F]FDG PET, a cohort of 35 patients was included. SUVs and tumor-to-background ratios (TBRs) for primary and metastatic lesions were systematically collected and analyzed. To evaluate FAP expression in tissue samples, H-scores were obtained from FAP-immunohistochemistry (FAP-IHC) analyses of samples from 28 patients and correlated with the SUVs measured in [18F]AlF-FAP-NUR PET scans. Statistical analyses included non-parametric tests and correlation assessments, with a significance threshold set at P